


REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L28 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:708311 HCAPLUS Full-text
DOCUMENT NUMBER: 121:308311
TITLE: Use of dinaphthalenes compounds as
antiproliferative agents
INVENTOR(S): Harris, Adrian Llewelyn; Bicknell, Roy;
Herlihy, Walter Curtin, Jr.; Rusche, James Robert;
Witt, Daniel Parker
PATENT ASSIGNEE(S): Imperial Cancer Research Technology Ltd., UK
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----
WO 9413277	A2	19940623	WO 1993-GB2493	
19931206 <--				
WO 9413277	A3	19940804		
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, RO, RU,		KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, SD, SE, SK, UA, US, UZ, VN		
		RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,		
		BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
AU 9456549	A	19940704	AU 1994-56549	
19931206 <--				
PRIORITY APPLN. INFO.:			GB 1992-25475	A
19921205 <--			WO 1993-GB2493	W
19931206 <--				
OTHER SOURCE(S): GI		MARPAT 121:308311		



AB Compds. such as suramin (I) or its derivs. or a pharmaceutically acceptable salt, ester, salt of such ester or amide of such compds., are used in the manufacture of a medicament for use in reducing undesired angiogenesis, treating cancer, treating fibrotic disease, or treating diseases benefiting from antagonism of the action of fibroblast, vascular endothelial and transforming growth factors. An example is given of inhibition of Swiss 3T3 fibroblast and capillary endothelial cell 3H-methylthymidine uptake by I and other compds. Pharmaceutical compns. of I and derivs. are given.


IT 157871-87-9P 157872-07-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 157871-87-9 HCPLUS


CN 1,3-Naphthalenedisulfonic acid, 7,7'-[carbonylbis(imino-3,1-phenylenecarbonylimino-3,1-phenylenecarbonylimino)]bis-,
tetrasodium salt
(9CI) (CA INDEX NAME)

PAGE 1-A



●4 Na


PAGE 1-B



RN 157872-07-6 HCPLUS


CN 1,3-Naphthalenedisulfonic acid, 6,6'-[carbonylbis(imino-3,1-phenylenecarbonylimino-3,1-phenylenecarbonylimino)]bis-,
tetrasodium salt
(9CI) (CA INDEX NAME)

PAGE 1-A



●4 Na

PAGE 1-B



IT 158195-75-6P, CPD 10 158195-76-7P, CPD 13

RL: PREP (Preparation)

(preparation of, as antiproliferative and angiogenesis-decreasing compound)


RN 158195-75-6 HCPLUS

CN 1,3-Naphthalenedisulfonic acid, 7,7'-[carbonylbis(imino-3,1-phenylene carbonylimino-3,1-phenylene carbonylimino)]bis- (9CI) (CA


INDEX

NAME)

PAGE 1-A



PAGE 1-B




RN 158195-76-7 HCPLUS

CN 1,3-Naphthalenedisulfonic acid, 6,6'-[carbonylbis(imino-3,1-phenylene carbonylimino-3,1-phenylene carbonylimino)]bis- (9CI) (CA

INDEX NAME)

PAGE 1-A



PAGE 1-B

